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RESPONSE TO “HIGH RISK OF NEUTROPENIA FOR HORMONE-NAIVE PROSTATE CANCER PATIENTS 
RECEIVING STAMPEDE-STYLE UPFRONT DOCETAXEL CHEMOTHERAPY IN USUAL CLINICAL 
PRACTICE” by DR TANGUAY et al 
 
Dr Tanguay and colleagues present data on patients treated with docetaxel.(1) We agree that the 
reported rates of neutropenia-based toxicities varies across the trials, as do the categories against 
which toxicities are reported (Table 1).  
 
We agree that docetaxel, like any chemotherapy, is not a risk-free and patients should be counselled 
appropriately of the risks when choosing their treatment strategy. We agree that particular thought 
is needed in men without metastases. The STAMPEDE paper presented an improvement in survival 
overall but that this was dominated by deaths in patients who had metastatic disease when joining 
the trial.(2) A sizeable improvement in failure-free survival was noted for men with and without 
metastases. 
 
Dr Tanguay and colleagues are not the first to point out that outcomes for patients treated outside 
trials may be less favourable than those treated in a trial situation,(3) but this is an important point 
in translation of results. We note that the sample size from one centre is modest at this time. 
 
Neutropenic sepsis does have fatal potential, so more consideration may be given to the use of 
G-CSF in the routine care of such patients. In STAMPEDE, G-CSF was permitted by institutional 
standards, but we did not collect information on its use. This will be collected prospectively in the 
ongoing trial comparisons for patients who having docetaxel as part of their standard-of-care. 
 
We thank the authors for their timely warning and encourage others to remain vigilant whilst giving 
this potent treatment, which we have shown to improve survival. 
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Table 1: Summary of neutropenia-based events reported 
 
 STAMPEDE  CHAARTED GETUG-15 GETUG-12 TAX3271 Velindre 
Reference (2) (4) (5) (6, 7) (8)  
Pts allocated DOC 592  390  205  189  332  39  
Setting First-line First-line First-line First-line CRPC First-line 
M1 at baseline 60% 100% 100% 0% 100% 59% 
             
Neutropenia 66  12% 47  12% 56 27% n/a  106 32% 14 36% 
Febrile neutropenia 84  15% 26 6% 5 2% 15 8% 10 3% n/a 
Infection +  
 neutropenia 
n/a 9  2% n/a 5 3% n/a n/a 
Neutropenic sepsis n/a n/a n/a n/a n/a2 8 20% 
 
1 3-week arm, and numbers estimated from % 
2 One fatalities from sepsis 
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